Study CR9112792: A 12-month, Randomized, Double-blind, Parallel-group, Placebo and Active-controlled Dose-range Finding Study of the Efficacy and Safety of SB-751689 in Post-menopausal Women With Osteoporosis.

Trial Profile

Study CR9112792: A 12-month, Randomized, Double-blind, Parallel-group, Placebo and Active-controlled Dose-range Finding Study of the Efficacy and Safety of SB-751689 in Post-menopausal Women With Osteoporosis.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Ronacaleret (Primary) ; Alendronic acid; Teriparatide
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 May 2010 Interim results were reported at the 2010 IOF World Congress on Osteoporosis and 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.
    • 08 May 2010 Results were reported at the 2010 IOF World Congress on Osteoporosis and 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.
    • 06 Apr 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov (NCT00471237).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top